Trial · NCT02623439
Adverse events20
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 20
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Human herpesvirus 6 (HHV-6) | Immune system disorders | cyclophosphamide post BMT | 1 | 8 | 2 |
| other | Enterococcus Faecalis UTI | Infections and infestations | cyclophosphamide post BMT | 1 | 8 | 1 |
| other | BC (+) Rothia mucilaginosa septicemia | Infections and infestations | cyclophosphamide post BMT | 1 | 8 | 1 |
| other | CMV | Immune system disorders | cyclophosphamide post BMT | 1 | 8 | 1 |
| other | acute GVHD | Immune system disorders | cyclophosphamide post BMT | 2 | 8 | 3 |
| other | aspergillosis | Immune system disorders | cyclophosphamide post BMT | 1 | 8 | 2 |
| other | stenotrophomomas pneumonia | Respiratory, thoracic and mediastinal disorders | cyclophosphamide post BMT | 1 | 8 | 2 |
| other | Cytokine storm | Blood and lymphatic system disorders | cyclophosphamide post BMT | 2 | 8 | 2 |
| other | vancomycin-resistant enterococcus (VRE) | Infections and infestations | cyclophosphamide post BMT | 1 | 8 | 1 |
| other | pulmonary infiltrates | Respiratory, thoracic and mediastinal disorders | cyclophosphamide post BMT | 1 | 8 | 1 |
| other | extended spectrum beta-lactamase (ESBL) E.Coli | Infections and infestations | cyclophosphamide post BMT | 1 | 8 | 1 |
| other | Systemic inflammatory response syndrome (SIRS) | Infections and infestations | cyclophosphamide post BMT | 1 | 8 | 1 |
| other | Clostridioides difficile or C-diff | Infections and infestations | cyclophosphamide post BMT | 2 | 8 | 2 |
| other | CMV viremia | Immune system disorders | cyclophosphamide post BMT | 1 | 8 | 1 |
| other | respiratory failure | Respiratory, thoracic and mediastinal disorders | cyclophosphamide post BMT | 1 | 8 | 1 |
| serious | Renal Failure | Renal and urinary disorders | cyclophosphamide post BMT | 1 | 8 | 1 |
| serious | CMV | Immune system disorders | cyclophosphamide post BMT | 1 | 8 | 2 |
| serious | Adenovirus | Immune system disorders | cyclophosphamide post BMT | 1 | 8 | 1 |
| serious | Acute GVHD | Immune system disorders | cyclophosphamide post BMT | 1 | 8 | 1 |
| serious | Respiratory Failure | Respiratory, thoracic and mediastinal disorders | cyclophosphamide post BMT | 1 | 8 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02623439/events